Blogs

CPHI Frankfurt 2025 is the year’s most efficient place to compare science, scale, and reliability in one hall. Sponsors meet teams, see facilities represented across regions, and validate claims in real time.

OROCIDIN A/S, a company focused on developing a novel treatment for advanced gum disease, or aggressive periodontitis, partnered with Syngene for the synthesis of their lead molecule

Time has always been the most serious concern in drug discovery, making it a race¾ not just to develop new treatments but also to deliver safe and effective medicines to patients more quickly.

One of the less obvious risks in drug development is not how a medicine works inside the body, but how it behaves in the real world, particularly when exposed to sunlight.

India supplies more than 20% of the world’s generic medicines, reaching over 200 countries. It provides 40% of generic drugs used in the U.S. and 80% of antiretrovirals globally, reinforcing its pivotal role in affordable global healthcare.

In the fast-paced world of drug discovery, every day counts—and so does every drop of solvent. Yet for chemists working with polar, unstable prodrugs and new chemical entities (NCEs), one critical step has remained frustratingly slow, expensive, and inefficient: purification.

In today’s rapidly evolving world, a resilient supply chain is no longer optional for the biopharma industry; it’s a strategic necessity.

Targeted protein degraders like PROTACs offer novel therapeutic potential but face ADME hurdles—poor solubility, permeability, and weak IVIVC. Experts Prasoon Chaturvedi (C4 Therapeutics), Vishwottam Kandikere, and Amol Raje (Syngene) discussed solutions.

Imagine a world where diseases once deemed “undruggable” are met with targeted, precise therapies. This vision is rapidly becoming a reality, thanks to the revolutionary technology of PROTACs (proteolysis-targeting chimeras).

As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.